Trial Profile
A randomized, double-blind, parallel group, placebo-controlled study to evaluate the efficacy, safety and tolerability of CR4056 administered for 2 weeks in patients with osteoarthritis of the knee with moderate to severe chronic pain (with or without a neuropathic component)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Sep 2020
Price :
$35
*
At a glance
- Drugs CR 4056 (Primary)
- Indications Neuropathic pain; Pain
- Focus Proof of concept; Therapeutic Use
- Sponsors Rottapharm Biotech
- 22 Aug 2020 Results presented at the 2020 World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases
- 22 Aug 2020 Results presented at the 2020 World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases
- 08 Nov 2017 Results presented at the 81st American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting